We aimed at examining sensitivity of combined visual and semi-quantitative <sup>123</sup>I-FP-CIT SPECT analyses in a prospective cohort of subjects with DLB and degenerative parkinsonisms - Parkinson's disease (PD), multiple system atrophy (MSA), corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP) to determine prevalence and clinical significance of scans without evidence of dopaminergic deficit (SWEDD).
In this study, abnormal <sup>123</sup>I-FP-CIT SPECT was strongly associated with underlying Lewy body disease pathology, supporting the utility of <sup>123</sup>I-FP-CIT SPECT in the clinical diagnosis of dementia with Lewy bodies.
Visual and semi-quantitative assessments of <sup>123</sup>I-FP-CIT single-photon emission computed tomography (SPECT) are useful for the diagnosis of dopaminergic neurodegenerative diseases (dNDD), including Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy, multiple system atrophy, and corticobasal degeneration.
To assess the validity of a semi-quantitative I-FP-CIT SPECT method, compared to the commonly used visual analysis, in patients with probable dementia with Lewy bodies (DLB) and Alzheimer's disease (AD).
It is widely known that there is low striatal <sup>123</sup>I-FP-CIT dopamine transporter single photon emission computed tomography (DAT-SPECT) uptake in patients with dementia with Lewy bodies (DLB).
This large autopsy analysis of <sup>123</sup>I-FP-CIT imaging in dementia demonstrates that it is a valid and accurate biomarker for DLB, and the high specificity compared with clinical diagnosis (20% higher) is clinically important.
It is widely known that there is low striatal <sup>123</sup>I-FP-CIT dopamine transporter-single photon emission tomography (DAT-SPECT) uptake in patients with dementia with Lewy bodies (DLB).